Photocure ASA · OSL:PHO

Photocure ASA — Merger or Acquisition (October 2010)

17 slides from Photocure ASA's merger presentation, Oct 20, 2010

  1. Slide 1: Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals

    Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan™ with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

  2. Slide 2: Agreement with Salix Pharmaceuticals Inc. for Lumacan

    Agreement with Salix Pharmaceuticals Inc. for Lumacan™ • Exclusive worldwide license - excluding the Nordic region- for development, registration and commercialisation of LumacanTM Photocure to receive: Salix to receive: • Signing fee of $4 million • Rights to IP related to the molecule hexylaminole

  3. Slide 3: In line with Photocure's strategic approach to business development and partnering

    In line with Photocure’s strategic approach to business development and partnering • Photocure’s main strategic target is to; • Build a profitable specialty pharma company • Maximise the potential of its innovative Photodynamic Tehcnology Platform • Leverage proven experience to develop register and

  4. Slide 4: Colorectal Cancer

    Colorectal Cancer • 3rd most commonly diagnosed cancer • 2nd most deadly cancer worldwide*, even though colon cancer is curable when diagnosed earlier • > 500,000 new cases and ~250,000 deaths from colon cancer each year in the US and EU • Current diagnosis has limitations • Smaller polyps/flat prec

  5. Slide 5: Lumacan

    Lumacan™ Offers improved diagnosis of colorectal cancer • LumacanTM - Photodynamic colorectal diagnosis • Increases detection rate for colon cancer • Fluorescence diagnosis • Used as adjunct to standard white light colonoscopy • Lumacan targets high-risk screening patients and diagnostics patients i

  6. Slide 6: Lumacan: Improved diagnosis of colorectal cancer

    Lumacan™ Improved diagnosis of colorectal cancer Proof of Concept study in Germany: Flat lesion showing fluorescence in colon (Courtesy: Prof. Dr. B. Mayinger) White light Blue light 6

  7. Slide 7: Strong Product Portfolio

    Strong Product Portfolio Clinical pipeline: Pre- PRODUCT INDICATION Phase I Phase II Phase III Market Status Clinical Detection of Marketed in Europe and Hexvix® bladder cancer US CANCER Treatment of Results expected Cevira™ precursors of Q1 2011 cervical cancer Detection of Licensed to Salix Lumaca

  8. Slide 8: Next Major Milestones

    Next Major Milestones Commercial: • GE Healthcare launch of CysviewTM in the US • Progress on commercial activities for Hexvix® in Europe • Prepare for first dermatology product launch in the US in 2011 Pipeline progress: • VisonacTM: Update on clinical development plan in Q4 2010 • CeviraTM: Final

  9. Slide 9: Summary

    Summary • Out-licensing of Lumacan in phase I/II is consistent with Photocure’s strategic approach to the cancer area • Salix Pharmaceuticals’ meet all Photocure’s criteria for partner selection, and the agreement offers the best way of accelerating the development of Lumacan and create value for Ph

  10. Slide 10: Photodynamic therapy and diagnosis

    Photodynamic therapy and diagnosis Earlier & more accurate diagnosis More targeted treatment Few/ limited side effects Well documented New standards for diagnosis & treatment of cancer Clinically validated – 2 on-market products and 3 products in the clinical pipeline 10

  11. Slide 11: Appendix

    Brilliance in photodynamic technology TM Appendix

  12. Slide 12: Salix Pharmaceuticals, Inc

    Salix Pharmaceuticals, Inc  Headquarter: Morrisville, North Carolina  Stock Exchange: NASDAQ  Employees: ~400  Sales force: ~160 employees  R&D: ~50 employees  2009 Sales: $230 million  2009 R&D: $90 million  Market Cap: $2.3 billion 12

  13. Slide 13: Mission Statement

    Brilliance in photodynamic technology TM Mission Statement Salix Pharmaceuticals is committed to being the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders. 13

  14. Slide 14: Global reach through key partnerships

    Global reach through key partnerships 14

  15. Slide 15: Salix Experience

    Salix Experience  Proven track record of acquiring products -14 products since inception  Success in progressing product candidates through late-stage development and FDA approval process - 7 NDA approvals and new product launches since 2000 - 2 NDAs pending approval  Specialty sales force - Aver

  16. Slide 16: Unique Prescribers

    205235 (Unique Prescribers) @ Products XIFAXAN XIFAXAN eo METOZOLV ODT APRISO Lan APRISO Purgatives = — Salix@

  17. Slide 17: Forward-Looking Statement

    Forward-Looking Statement Statements presented in this overview that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from projected results. Factors that could cause actual results to differ materially

Photocure — Merger or Acquisition (October 2010) on 6ix